We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Deletion of early Wuhan cases evidence of ‘deliberate obfuscation’ of Covid’s origins, expert says
US health agency says Covid-19 vaccine benefits still outweigh small risk of rare condition in adolescents
NHS and mayor to attend community summit as UK reports most daily infections since February
Anger at prospect of senior officials attending climax of football tournament in London despite quarantine rules
Cases surge across the continent as vaccine rollout moves slowly
Potential treatments for addiction and mental illnesses are gathering pace
City has gambled on keeping its border open to the world during the pandemic
Country’s inoculation drive has faltered after a blistering start
Hong Kong-based platform has 16 programmes in development including potential cancer and Covid treatments
Former adviser, in online Q&A on time in No 10, describes PM as ‘pundit who stumbled into politics’
Johnson says priority is to keep people safe in Britain but suggests relaxation of quarantine rules being examined
Group behind AstraZeneca jab believes it has better chance of success in tackling tumours
Three-jab Soberana 2 has 62% efficacy after two doses, interim trial data show
Government racing to fully inoculate all over-50s and offer first dose of jab to all adults
Strain that swept UK has become dominant in Portugal and appeared in clusters across Germany, France and Spain
Data suggest early surge from Delta variant may have given way to steady climb
As Covid restrictions lift, many people are anxious about attending mass events or even commuting
German drugmaker believes jab could still be used for some age groups or as booster
New infections mean 30 to 39-year-olds at more risk from Covid than vaccine-related blood clots, FT analysis shows
Testing may enable wealthy nations to donate their booster shots to help the poorest countries
German biotech group’s shares plunge after interim results show jab only 47% effective
International Edition
